EUVIMEDEUVIMED entdecken
Crossref

Odronextamab: First Approval

Hannah A Blair

Drugs · 2024-12 · 84 (12) · 1651-1658

DOI: 10.1007/s40265-024-02112-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs, online erschienen am 19.11.2024. Verfasst von Hannah A Blair. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Drug Approval, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Odronextamab (Ordspono™), a CD20xCD3 bispecific antibody, is being developed by Regeneron Pharmaceuticals for the treatment of B-cell non-Hodgkin's lymphoma. On 26 August 2024, odronextamab received its first approval in the EU as monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) or relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of systemic therapy. Clinical trials in various other B-cell non-Hodgkin's lymphoma, including mantle cell lymphoma, marginal zone lymphoma and chronic lymphocytic leukaemia, are underway in multiple countries. This article summarizes the milestones in the development of odronextamab leading to this first approval for the treatment of adult patients with relapsed/refractory FL or relapsed/refractory DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificDrug ApprovalLymphoma, FollicularLymphoma, Large B-Cell, DiffuseAdultHumansAntigens, CD20Antineoplastic Agents

Substanzen

Antibodies, BispecificAntigens, CD20Antineoplastic Agents

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Blair, H. A. (2024). Odronextamab: First Approval. Drugs, 84(12), 1651-1658. https://doi.org/10.1007/s40265-024-02112-6

Vancouver

Blair HA. Odronextamab: First Approval. Drugs. 2024;84(12):1651-1658. doi:10.1007/s40265-024-02112-6

BibTeX
@article{Blair2024,
  author = {Blair, Hannah A},
  title = {Odronextamab: First Approval},
  journal = {Drugs},
  year = {2024},
  volume = {84},
  number = {12},
  pages = {1651--1658},
  doi = {10.1007/s40265-024-02112-6}
}
Kostenlos starten →